Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2018-09-13 Declaration of Voting R…
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Disclosure of voting rights for Chairman of the Board
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it is a 'Disclosure of voting rights for Chairman of the Board' and details the number of shares held directly and the number of shares represented via powers of attorney by the Chairman for an upcoming extraordinary general meeting. This directly relates to insider transactions or holdings of key personnel, which falls under Director's Dealing (DIRS) or potentially a specific voting rights disclosure. Given the options, 'Director's Dealing (DIRS)' is the closest fit as it reports on the personal share transactions/holdings of a director (Chairman). Although it is related to an EGM, it is a disclosure of voting power/holding, not the results (DVA) or the proxy materials (PSI). Since it details the holdings and voting rights representation of a director, DIRS is the most appropriate classification.
2018-09-13 English
PCI Biotech: Second quarter and first half-year 2018 results
Interim / Quarterly Report Classification · 100% confidence The document is a 'Second Quarter and First Half-Year Report' for 2018, containing detailed financial tables (Key Figures), operational reviews, and management commentary on clinical programs. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2018
2018-08-30 English
PCI Biotech: Second quarter and first half-year 2018 results
Investor Presentation Classification · 98% confidence The document is titled 'Q2 & 1H 2018 PRESENTATION' and contains detailed slides covering financial updates, clinical trial progress (fimaCHEM, fimaVACC), technology explanations, and corporate strategy. The content structure, including CEO/CFO commentary, forward-looking statements, and specific data points for half-year (1H) and second quarter (Q2) performance, strongly indicates an Investor Presentation. It is not a formal regulatory filing like a 10-K or an Earnings Release (ER) which usually contains only the summary figures. It is too detailed and structured for a simple Report Publication Announcement (RPA). Therefore, Investor Presentation (IP) is the most appropriate classification.
2018-08-30 English
PCI Biotech: Second quarter and first half-year 2018 results
Earnings Release Classification · 96% confidence The document explicitly states it announces the 'interim second quarter and first half-year 2018 result' and mentions that the 'report and presentation' are enclosed. This strongly indicates the release of periodic financial results, which aligns with the definition of an Interim/Quarterly Report (IR). However, the text also mentions that the presentation will be held today and provides links to attachments, suggesting it is an announcement *about* the release of the results and associated materials. Since the document summarizes key financial and operational highlights (like the rights issue and clinical study updates) and is titled as the result announcement, it functions primarily as an Earnings Release (ER) or Interim Report (IR). Given the explicit mention of 'interim second quarter and first half-year 2018 result' and the inclusion of detailed operational updates, 'IR' (Interim / Quarterly Report) is the most precise fit, as it covers comprehensive period results shorter than a year. If it were just a brief announcement pointing to the full report, RPA would be considered, but this text contains substantial content summarizing the period's performance. H1 2018
2018-08-30 English
Key information relating to the preferential rights issue to be carried out by PCI Biotech Holding ASA
Capital/Financing Update Classification · 98% confidence The document text explicitly details key information regarding a 'preferential rights issue' by PCI Biotech Holding ASA, including dates for ex-date, record date, subscription price, and the maximum number of new shares. This content directly relates to a capital structure change or fundraising activity. Based on the definitions, 'Capital/Financing Update' (CAP) is the most appropriate classification, as it covers company fundraising and capital structure changes. The document is short and provides specific details rather than announcing the publication of a larger report.
2018-08-24 English
PCI Biotech: Notice of Extraordinary General Meeting
AGM Information Classification · 99% confidence The document text explicitly states 'INNKALLING TIL EKSTRAORDINÆR GENERALFORSAMLING' (NOTICE OF EXTRAORDINARY GENERAL MEETING) in both Norwegian and English. It details the time, place, agenda items (including a proposed 'Guaranteed rights issue'), procedures for attendance, voting, and proxies for this meeting. This content is characteristic of a formal notice calling for a shareholder meeting, which aligns directly with the definition of AGM Information (AGM-R), even though it is an 'Extraordinary' meeting rather than the standard Annual General Meeting. The document is the notice itself, not the minutes or voting results.
2018-08-24 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.